ArticleBMJ open respiratory research2026
Exacerbation-related burden in patients with severe asthma in South Korea: a population-based cohort study.
Article in BMJ open respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe burden of severe asthma due to asthma exacerbation is increasing. However, recent studies identifying exacerbation-related disease burden among patients with severe asthma in South Korea are lacking.
objectiveTo evaluate the burden of asthma exacerbations in patients with severe asthma in South Korea.
methodsA retrospective cohort study using National Health Insurance data from 2016 to 2019 was conducted. Patients with severe asthma were defined as satisfying the following criteria: (1) having been prescribed ≥1 inhaled corticosteroid-long-acting β-2 agonist and long-acting muscarinic antagonist with a diagnosis of asthma; (2) having experienced ≥4 asthma exacerbation events within 1 year, after meeting the first criterion. Exacerbation was defined as a corticosteroid burst. Healthcare utilisation, direct medical costs and case fatality rates related to asthma exacerbations were identified during the follow-up period.
resultsOutpatient visits accounted for 81.26% of all exacerbation events, followed by general ward hospitalisation (14.55%). The exacerbation-related costs were as follows: outpatient visit, $29.89; emergency room visit, $95.02; general ward hospitalisation, $1929.32; and intensive care unit admission, $7918.86. The case fatality rates were 2.65% for patients with asthma, 3.16% for patients who had exacerbations and 6.96% for patients who had exacerbations with hospitalisation.
conclusionThis study is the first population-based cohort study observing exacerbation-related burdens in patients with severe asthma, using recent data and generating real-world evidence. The results of this study can be used as evidence for further research on the burden of asthma and to inform decision-making in healthcare policy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.